Sabine D. Brookman-May retweeted
🎯 Mature THOR data confirm that FGFR3 is an actionable target in metastatic urothelial cancer!
Erdafitinib vs chemotherapy:
🔹 OS: 12.1 vs 8.7 months (HR 0.65)
🔹 ORR: 46.9% vs 12.6%
But the survival curves also highlight the challenge: most patients progress.
How can we sponses?
Overcoming adaptive resistance will be key. NRG1–ERBB signaling is one intriguing avenue, as explored in our previous work (Hosni et al. @CR_AACR)
Could rational combinations, including FGFR inhibition + EV, improve outcomes? FORAGER-2 is particularly interesting @EliLillyandCo @loredana_puca
Precision targeting works. Now we need to make responses last. 🔬
@OncoAlert @weoncologists @urotoday @Uromigos
@OncoAlert and Faculty: @DrChoueiri @tompowles1 @apolo_andrea @neerajaiims @montypal @Silke_Gillessen @AOmlin @brian_rini @PGrivasMDPhD @TiansterZhang @amerseburger @DrDanielHeng @HHammersMD @scocmem @AndreaNecchi @AmandaNizamMD @drenriquegrande @nataliagandur @AlbigesL @cdanicas @declangmurphy @seanmmcbride @shilpaonc @DrRanaMcKay @scserendipity1 @DrYukselUrun @ravikanesvaran @BraunMDPhD @EfstathiouEleni @mzugman @crisbergerot @Markuseckstein3
Erdafitinib vs chemotherapy:
🔹 OS: 12.1 vs 8.7 months (HR 0.65)
🔹 ORR: 46.9% vs 12.6%
But the survival curves also highlight the challenge: most patients progress.
How can we sponses?
Overcoming adaptive resistance will be key. NRG1–ERBB signaling is one intriguing avenue, as explored in our previous work (Hosni et al. @CR_AACR)
Could rational combinations, including FGFR inhibition + EV, improve outcomes? FORAGER-2 is particularly interesting @EliLillyandCo @loredana_puca
Precision targeting works. Now we need to make responses last. 🔬
@OncoAlert @weoncologists @urotoday @Uromigos
@OncoAlert and Faculty: @DrChoueiri @tompowles1 @apolo_andrea @neerajaiims @montypal @Silke_Gillessen @AOmlin @brian_rini @PGrivasMDPhD @TiansterZhang @amerseburger @DrDanielHeng @HHammersMD @scocmem @AndreaNecchi @AmandaNizamMD @drenriquegrande @nataliagandur @AlbigesL @cdanicas @declangmurphy @seanmmcbride @shilpaonc @DrRanaMcKay @scserendipity1 @DrYukselUrun @ravikanesvaran @BraunMDPhD @EfstathiouEleni @mzugman @crisbergerot @Markuseckstein3
1
18
31
2,214
Sabine D. Brookman-May retweeted
🚀 Is GU oncology becoming one of the most exciting fields for molecular imaging & theranostics?
PSMA in prostate cancer, CAIX in clear-cell RCC, and emerging NECTIN4-targeted approaches in urothelial cancer!
Fantastic to see CAIX imaging on the cover of The Lancet Medical ImagIX is a particularly elegant target: VHL loss → HIF stabilization → CAIX upregulation in ccRCC.
Using tumor biology wisely! 🧬
The opportunity goes beyond detecting disease: molecular imaging could enable patient selection, visualize target heterogeneity and potentially guide radioligand therapy.
Of course, CAIX-directed theranostics still require prospective validation, particularly of therapeutic efficacy and safety.
Exciting times for precision GU oncology! 👏
Read here: sciencedirect.com/science/articl…
@ProfKHerrmann
#KidneyCancer #Theranostics #GUOncology
@weoncologists @urotoday @Uromigos
@OncoAlert and Faculty: @DrChoueiri @tompowles1 @apolo_andrea @neerajaiims @montypal @Silke_Gillessen @AOmlin @brian_rini @PGrivasMDPhD @TiansterZhang @amerseburger @DrDanielHeng @HHammersMD @scocmem @AndreaNecchi @AmandaNizamMD @drenriquegrande @nataliagandur @AlbigesL @cdanicas @declangmurphy @seanmmcbride @shilpaonc @DrRanaMcKay @scserendipity1 @DrYukselUrun @ravikanesvaran @BraunMDPhD @EfstathiouEleni @mzugman @crisbergerot @Markuseckstein3
PSMA in prostate cancer, CAIX in clear-cell RCC, and emerging NECTIN4-targeted approaches in urothelial cancer!
Fantastic to see CAIX imaging on the cover of The Lancet Medical ImagIX is a particularly elegant target: VHL loss → HIF stabilization → CAIX upregulation in ccRCC.
Using tumor biology wisely! 🧬
The opportunity goes beyond detecting disease: molecular imaging could enable patient selection, visualize target heterogeneity and potentially guide radioligand therapy.
Of course, CAIX-directed theranostics still require prospective validation, particularly of therapeutic efficacy and safety.
Exciting times for precision GU oncology! 👏
Read here: sciencedirect.com/science/articl…
@ProfKHerrmann
#KidneyCancer #Theranostics #GUOncology
@weoncologists @urotoday @Uromigos
@OncoAlert and Faculty: @DrChoueiri @tompowles1 @apolo_andrea @neerajaiims @montypal @Silke_Gillessen @AOmlin @brian_rini @PGrivasMDPhD @TiansterZhang @amerseburger @DrDanielHeng @HHammersMD @scocmem @AndreaNecchi @AmandaNizamMD @drenriquegrande @nataliagandur @AlbigesL @cdanicas @declangmurphy @seanmmcbride @shilpaonc @DrRanaMcKay @scserendipity1 @DrYukselUrun @ravikanesvaran @BraunMDPhD @EfstathiouEleni @mzugman @crisbergerot @Markuseckstein3
2
23
68
3,601
Sabine D. Brookman-May retweeted
🚀 Exciting work by @brian_rini and colleagues! IRIS-RCC brings us closer to reproducible, individual-sample molecular subtyping in RCC.
We are exploring a complementary approach in mRCC: vascular architecture as a biomarker of IO sensitivity, assessed on routine H&E or CD31 IHC.
Our initial data suggest that low vessel branching may enrich for IO response, while our vascular score has also shown baseline prognostic value in CheckMate 914.
The exciting opportunity: a potentially scalable, pathology-based biomarker that could be easier to integrate into routine clinical workflows.
Next step: validation in digitized H&E from large, randomized mRCC cohorts—critically, to distinguish predictive from prognostic value.
Our preprint 👇
medrxiv.org/content/10.110…
@OncoAlert @weoncologists @DrChoueiri
We are exploring a complementary approach in mRCC: vascular architecture as a biomarker of IO sensitivity, assessed on routine H&E or CD31 IHC.
Our initial data suggest that low vessel branching may enrich for IO response, while our vascular score has also shown baseline prognostic value in CheckMate 914.
The exciting opportunity: a potentially scalable, pathology-based biomarker that could be easier to integrate into routine clinical workflows.
Next step: validation in digitized H&E from large, randomized mRCC cohorts—critically, to distinguish predictive from prognostic value.
Our preprint 👇
medrxiv.org/content/10.110…
@OncoAlert @weoncologists @DrChoueiri
Several groups have attempted to predict the IM151 RCC clusters with flawed methods. We developed IRIS-RCC (Individual RNA-seq Intrinsic Subtyping for RCC; available at irisrcc.vindhyadatascience.com), to predict clusters using an individual-sample model.
nature.com/articles/s4169…
1
4
10
924
Sabine D. Brookman-May retweeted
Free education and networking event for GU oncology in La Jolla next week.
@OncLive @DrRanaMcKay Rahul Aggarwal @YuWeiChenMD
@UCSFCancer @UCSDCancer
Would love to see you + your colleagues: @montypal @AmarUKishan @Adam_Weiner535 @jgong15 @yunroseli @EdwinPosadasMD
@OncLive @DrRanaMcKay Rahul Aggarwal @YuWeiChenMD
@UCSFCancer @UCSDCancer
Would love to see you + your colleagues: @montypal @AmarUKishan @Adam_Weiner535 @jgong15 @yunroseli @EdwinPosadasMD
1
3
9
1,342
Interesting data from Phase 2 study #COMRADE at #ESMO26: Early on-treatment #ctDNA may help identify patients at risk of progression after just one cycle of #radium223. Possibly one more step toward biomarker-guided, adaptive radiopharmaceutical therapy.
We are getting more and more evidence about a potential key prognostic role of ctDNA also in #ProstateCancer including evidence that it may be used as a guide for treatment modulation - it will be most important now to prospectively include ctDNA in more trials and further validate it #mCRPC #RLT #Olaparib #radium223 @urotoday @oncodaily @OncoDailyGU @DrRanaMcKay
We are getting more and more evidence about a potential key prognostic role of ctDNA also in #ProstateCancer including evidence that it may be used as a guide for treatment modulation - it will be most important now to prospectively include ctDNA in more trials and further validate it #mCRPC #RLT #Olaparib #radium223 @urotoday @oncodaily @OncoDailyGU @DrRanaMcKay
Longitudinal ctDNA Tumor Fraction in Bone-Dominant #mCRPC Treated with Radium-223 ± Olaparib: Results from the Phase 2 COMRADE Trial. Presented by @DrRanaMcKay @UCSanDiego. #ESMO26 written coverage by @RKSayyid @UAUrology > bit.ly/4eAzxVR #ProstateCancer #Pr
0
3
7
510
And confirmed again that #PSA Nadir (cut-off 0.2 l) is a strong prognostic factor and predictor of oncological outcomes OS, CRPC-FS in patients with #mAPMS PC.
A higher proportion of patients treated with ADT+ARPI compared to ADT+Docetaxel or ADT+D+ARPI achieved a deep PSA y interested in seeing the breakdown per treatment in both low and high volume categories, but I guess the nadir achieved reflects predominantly more aggressive disease rather than a treatment effect #ProstateCancer #UrologicOncology #PSANadir #Biomarkers @oncodaily @OncoDailyGU @urotoday @chavarriagaj
A higher proportion of patients treated with ADT+ARPI compared to ADT+Docetaxel or ADT+D+ARPI achieved a deep PSA y interested in seeing the breakdown per treatment in both low and high volume categories, but I guess the nadir achieved reflects predominantly more aggressive disease rather than a treatment effect #ProstateCancer #UrologicOncology #PSANadir #Biomarkers @oncodaily @OncoDailyGU @urotoday @chavarriagaj
PSA Nadir >0.2 ng/mL Defines a Biologically Aggressive Subgroup in Metastatic Hormone-Sensitive #ProstateCancer. Presented by Dr. Nely Mercy Diaz Mejia. #ESMO26 written coverage by @chavarriagaj > bit.ly/4khD5Qn #mHSPC #PrecisionOncology @myESMO
1
3
9
631
Sabine D. Brookman-May retweeted
Just happened today👏🎉👉 @FDA approved Talazoparib + enzalutamide for pts with HRRm positive mAPMS/mHSPC #prostatecancer FDA Link👉 l1nq.com/ltlq6jk 👉 @NEJM paper tinyurl.com/vkvra8cd 👇 @ASCO @OncoAlert @urotoday @PCF_Science @DanaFarber_GU
Breaking news #ASCO26 Adding Talazoparib to enzalutamide significantly ⬆️ rPFS 👉 HR 0.48 in pts w/ mCSPC (mAPMS) #prostatecancer w/ HRRm 👉 @NEJM paper tinyurl.com/vkvra8cd 👇 @ASCO @oncoalert @urotoday @PCF_Science @OpenMedicineHQ
6
51
134
9,313
Sabine D. Brookman-May retweeted
LuCAB at #ESMO26 - Combination Lu-177 PSMA-617 + cabazitaxel in mCRPC, accepted in @TheLancetOncol
Adding taxane chemotherapy to LuPSMA may overcome heterogeneous PSMA expression and act as a radiosensitiser.
35 pts, post-docetaxel + ARPI:
🧪 No DLTs: cabazitaxel 20 mg/m2 + AEs 24%, no G4/5
📈 RP2D (n=26): PSA50 73%, rPFS 10.9 mo, OS 16.5 mo
Impressive outcomes in an unfavourable cohort (29% M1c).
Randomised trials needed: chemo + LuPSMA together or in sequence?
🙏 Led by @LouiseKostos & @AzadOncology with @ButeauJames , Grace Kong, @pj_physics, @DrBenTran, @MHaskali, @declangmurphy @PeterMacCC and @drlouiseemmett @StVincentsSyd
Above all, thank you to the patients and families who took part.
Funded by @PCFnews through @pros_tic , with PSMA-617 supplied by @Novartis plus additional support.
@myESMO
Adding taxane chemotherapy to LuPSMA may overcome heterogeneous PSMA expression and act as a radiosensitiser.
35 pts, post-docetaxel + ARPI:
🧪 No DLTs: cabazitaxel 20 mg/m2 + AEs 24%, no G4/5
📈 RP2D (n=26): PSA50 73%, rPFS 10.9 mo, OS 16.5 mo
Impressive outcomes in an unfavourable cohort (29% M1c).
Randomised trials needed: chemo + LuPSMA together or in sequence?
🙏 Led by @LouiseKostos & @AzadOncology with @ButeauJames , Grace Kong, @pj_physics, @DrBenTran, @MHaskali, @declangmurphy @PeterMacCC and @drlouiseemmett @StVincentsSyd
Above all, thank you to the patients and families who took part.
Funded by @PCFnews through @pros_tic , with PSMA-617 supplied by @Novartis plus additional support.
@myESMO
2
31
50
3,204
Positive DASL-HiCaP results presented at #ESMO26 @niazi_Dr7
👍Adding #darolutamide to ADT + RT in very-high-risk #ProstateCancer improved
✅4-year MFS (95% vs 88%; HR 0.42), ✅delayed CRPC (HR 0.22)
✅increased time to subsequent hormonal therapy (HR 0.36)
All clinically ile OS remains immature.
#ProstateCancer #Radiationtherapy #UrologicOncology @oncodaily @OncoDailyGU @urotoday @ChrisSweens1
👍Adding #darolutamide to ADT + RT in very-high-risk #ProstateCancer improved
✅4-year MFS (95% vs 88%; HR 0.42), ✅delayed CRPC (HR 0.22)
✅increased time to subsequent hormonal therapy (HR 0.36)
All clinically ile OS remains immature.
#ProstateCancer #Radiationtherapy #UrologicOncology @oncodaily @OncoDailyGU @urotoday @ChrisSweens1
1
6
9
876
While DASL-HiCaP reinforces ARPI intensification, important questions remain @Silke_Gillessen
Why positive #STAMPEDE/#DASL-HiCaP, yet not #ENZARAD? Which high-risk patients benefit most? Primary vs salvage RT? And how does #PROTEUS reshape intensification around surgery? ide #Darolutamide
❓Different risk definitions and primary vs salvage settings complicate comparisons.
❓Who truly needs ARPI intensification, and when? What is the additive role of #RadiationTherapy and #RadicalProstatectomy
❓With PROTEUS extending the discussion to prostatectomy, better patient selection and identifying the best prognostic and predictive biomarkers reflecting specific early/local/locally advanced indications remains key
#ESMO26 #ProstateCancer #UrologicOncology @oncodaily @OncoDailyGU @urotoday
Why positive #STAMPEDE/#DASL-HiCaP, yet not #ENZARAD? Which high-risk patients benefit most? Primary vs salvage RT? And how does #PROTEUS reshape intensification around surgery? ide #Darolutamide
❓Different risk definitions and primary vs salvage settings complicate comparisons.
❓Who truly needs ARPI intensification, and when? What is the additive role of #RadiationTherapy and #RadicalProstatectomy
❓With PROTEUS extending the discussion to prostatectomy, better patient selection and identifying the best prognostic and predictive biomarkers reflecting specific early/local/locally advanced indications remains key
#ESMO26 #ProstateCancer #UrologicOncology @oncodaily @OncoDailyGU @urotoday
0
2
5
270
Sabine D. Brookman-May retweeted
Dear GU colleagues at #ESMO26!
Dr. Silke Gillessen 🇨🇭invites you to the inaugural LPCCC – Localised Prostate Cancer Consensus Conference!
🔬 CALL FOR ABSTRACTS NOW OPEN!
👉 Submit your abstract: apccc.org/call-for-abstr…
📅 LPCCC 2027 | 29 April – 1 May 2027
We invite our Cancer to submit their abstracts and contribute to shaping the discussion on the diagnosis and clinical management of men with localised prostate cancer.
LPCCC marks an exciting evolution of the APCCC family, extending the consensus-conference concept to localised disease, with a particular focus on areas where evidence, guidelines and clinical practice leave important questions unanswered.
Two days of high-level presentations, discussion and debate will bring together the latest evidence and expert perspectives to address the questions that matter most in everyday clinical practice.
We look forward to your contributions!
#LPCCC27 #ProstateCancer #ASTRO26
@APCCC_Lugano, @BertrandTOMBAL, @ChrisSweens1, @jmmrad, @drjefstathiou, @CaPsurvivorship, @LoebStacy, @charlesryanmd, @AarmstrongDuke, @Ecastromarcos, @LVM_Walz, @piet_ost, @Nicola_Fossati, @AnthonyMJoshua, @Prof_Nick_James, @VedangMurthy, @AttardLab, @Silke_Gillessen, @AOmlin, @ProfKHerrmann
Pinging @AmandaNizamMD, @scocmem, @nataliagandur, @gu_onc, @tompowles1, @brian_rini, @declangmurphy, @cdanicas, @neerajaiims
Dr. Silke Gillessen 🇨🇭invites you to the inaugural LPCCC – Localised Prostate Cancer Consensus Conference!
🔬 CALL FOR ABSTRACTS NOW OPEN!
👉 Submit your abstract: apccc.org/call-for-abstr…
📅 LPCCC 2027 | 29 April – 1 May 2027
We invite our Cancer to submit their abstracts and contribute to shaping the discussion on the diagnosis and clinical management of men with localised prostate cancer.
LPCCC marks an exciting evolution of the APCCC family, extending the consensus-conference concept to localised disease, with a particular focus on areas where evidence, guidelines and clinical practice leave important questions unanswered.
Two days of high-level presentations, discussion and debate will bring together the latest evidence and expert perspectives to address the questions that matter most in everyday clinical practice.
We look forward to your contributions!
#LPCCC27 #ProstateCancer #ASTRO26
@APCCC_Lugano, @BertrandTOMBAL, @ChrisSweens1, @jmmrad, @drjefstathiou, @CaPsurvivorship, @LoebStacy, @charlesryanmd, @AarmstrongDuke, @Ecastromarcos, @LVM_Walz, @piet_ost, @Nicola_Fossati, @AnthonyMJoshua, @Prof_Nick_James, @VedangMurthy, @AttardLab, @Silke_Gillessen, @AOmlin, @ProfKHerrmann
Pinging @AmandaNizamMD, @scocmem, @nataliagandur, @gu_onc, @tompowles1, @brian_rini, @declangmurphy, @cdanicas, @neerajaiims
0
13
19
2,534
Sabine D. Brookman-May retweeted
Honoured to have had the opportunity to present "Optimal induction treatment in non-metastatic bladder cancer" at #ESMO26 in Madrid!
🚨 Does a deeper pathological response translate into greater survival benefit in perioperative MIBC?
An intriguing pattern across four phase III +10 pp | EFS HR 0.68
🔹 KEYNOTE-B15: +23 pp | HR 0.53
🔹 VOLGA: +32 pp | HR 0.51
🔹 KEYNOTE-905: +49 pp | HR 0.40
Larger absolute pCR gains appear to track with greater EFS benefit.
But the comparator matters!
KEYNOTE-905 and VOLGA used surgery-based controls without neoadjuvant systemic therapy (control "pCR" ~8–9%), whereas NIAGARA and KEYNOTE-B15 used active neoadjuvant cisplatin-based chemotherapy.
Thus, the magnitude of ΔpCR is not directly comparable across trials.
The key question: Can pCR, combined with utDNA + ctDNA clearance, become a reliable tool for response-adapted treatment intensity?
⚠️ This is an exploratory, trial-level observation—not proof that pCR improvements cause EFS benefits or that pCR is a validated surrogate endpoint!
Better biomarkers could help us maximize cure while minimizing overtreatment. 🔬
#ESMO26 #BladderCancer
@weoncologists @urotoday @Uromigos
@OncoAlert Faculty: @DrChoueiri @tompowles1 @apolo_andrea @neerajaiims @montypal @Silke_Gillessen @AOmlin @brian_rini @PGrivasMDPhD @TiansterZhang @amerseburger @DrDanielHeng @HHammersMD @scocmem @AndreaNecchi @AmandaNizamMD @drenriquegrande @nataliagandur @AlbigesL @cdanicas @declangmurphy @seanmmcbride @shilpaonc @DrRanaMcKay @scserendipity1 @DrYukselUrun @ravikanesvaran @BraunMDPhD @EfstathiouEleni @mzugman @crisbergerot @Markuseckstein3
🚨 Does a deeper pathological response translate into greater survival benefit in perioperative MIBC?
An intriguing pattern across four phase III +10 pp | EFS HR 0.68
🔹 KEYNOTE-B15: +23 pp | HR 0.53
🔹 VOLGA: +32 pp | HR 0.51
🔹 KEYNOTE-905: +49 pp | HR 0.40
Larger absolute pCR gains appear to track with greater EFS benefit.
But the comparator matters!
KEYNOTE-905 and VOLGA used surgery-based controls without neoadjuvant systemic therapy (control "pCR" ~8–9%), whereas NIAGARA and KEYNOTE-B15 used active neoadjuvant cisplatin-based chemotherapy.
Thus, the magnitude of ΔpCR is not directly comparable across trials.
The key question: Can pCR, combined with utDNA + ctDNA clearance, become a reliable tool for response-adapted treatment intensity?
⚠️ This is an exploratory, trial-level observation—not proof that pCR improvements cause EFS benefits or that pCR is a validated surrogate endpoint!
Better biomarkers could help us maximize cure while minimizing overtreatment. 🔬
#ESMO26 #BladderCancer
@weoncologists @urotoday @Uromigos
@OncoAlert Faculty: @DrChoueiri @tompowles1 @apolo_andrea @neerajaiims @montypal @Silke_Gillessen @AOmlin @brian_rini @PGrivasMDPhD @TiansterZhang @amerseburger @DrDanielHeng @HHammersMD @scocmem @AndreaNecchi @AmandaNizamMD @drenriquegrande @nataliagandur @AlbigesL @cdanicas @declangmurphy @seanmmcbride @shilpaonc @DrRanaMcKay @scserendipity1 @DrYukselUrun @ravikanesvaran @BraunMDPhD @EfstathiouEleni @mzugman @crisbergerot @Markuseckstein3
2
16
39
1,932
Sabine D. Brookman-May retweeted
🚨📣📣 #ESMO26 presidential: @niazi_Dr7 Adding darolutamide to ADT + RT dramatically ⬇️ risk of metastasis or death in high-risk localized prostate cancer. Phase 3 DASL-HiCaP = 58% ⬇️ in MFS (HR 0.42) + early OS signal (HR 0.88). #ProstateCancer #RadOnc #pcsm @ChrisSweens1
8
67
147
12,806
Sabine D. Brookman-May retweeted
Darolutamide with ADT and locoregional
radiation therapy (RT) in high-risk prostate cancer (DASL) showed Darolutamide reduced the risk of relapse and time to CRPC. Tolerably was good. It’s imporant to identity which patients benefit, as mortality is low, and whether latest hanges things #ESMO26 @Silke_Gillessen @ChrisSweens1
radiation therapy (RT) in high-risk prostate cancer (DASL) showed Darolutamide reduced the risk of relapse and time to CRPC. Tolerably was good. It’s imporant to identity which patients benefit, as mortality is low, and whether latest hanges things #ESMO26 @Silke_Gillessen @ChrisSweens1
1
47
98
4,745
Great to finally see the results of the #PROTEUS substudy comparing #perioperative Apa+ADT with the true SOC (RP w/o neoadjuvant treatment) - which should at least reduce some concerns related to the active comparator with ADT in the main study that didn’t reflect what we rd in HR patients #ESMO26
Outcomes in all #endpoints significant improved
✅EFS: HR 0.38, 95% CI 0.26–0.55
✅MFS: HR 0.49, 95% CI 0.26–0.90
✅TT 1st Sub Rx: HR 0.29, 95% CI 0.20–0.43
The question remains which of these outcomes are most clinically relevant and meaningful #PROTEUS #ProstateCancer #UrologicOncology #Apalutamide #RadicalProstatectomy @oncodaily @OncoDailyGU @urotoday @Albert0Briganti @JNJInnovMed
Outcomes in all #endpoints significant improved
✅EFS: HR 0.38, 95% CI 0.26–0.55
✅MFS: HR 0.49, 95% CI 0.26–0.90
✅TT 1st Sub Rx: HR 0.29, 95% CI 0.20–0.43
The question remains which of these outcomes are most clinically relevant and meaningful #PROTEUS #ProstateCancer #UrologicOncology #Apalutamide #RadicalProstatectomy @oncodaily @OncoDailyGU @urotoday @Albert0Briganti @JNJInnovMed
0
13
27
1,315
Sabine D. Brookman-May retweeted
🚽 Is Gem/Doce the Future for Bladder Cancer Treatment?
Gem/Doce shows promise as a first-line treatment for BCG-naïve high-risk NMIBC, offering new hope during BCG shortages.
📈 Efficacy - 3-year high-grade recurrence-free survival is 80%
🔬 Tolerability - Only 8% stopped due Future Potential - Phase 3 trials needed for standard care status
#BladderCancer #GemDoce #ClinicalTrials
tnyp.me/xRumFw21/x
Gem/Doce shows promise as a first-line treatment for BCG-naïve high-risk NMIBC, offering new hope during BCG shortages.
📈 Efficacy - 3-year high-grade recurrence-free survival is 80%
🔬 Tolerability - Only 8% stopped due Future Potential - Phase 3 trials needed for standard care status
#BladderCancer #GemDoce #ClinicalTrials
tnyp.me/xRumFw21/x
3
30
57
11,420
Couldn’t agree more @niklas_kluemper
It is our responsibility as urologists to make sure that patients receive the most appropriate treatment and that we consider perioperative treatment with #EVP. Most of the patient patients eligible for #RadicalCystectomy will also be eligible for EVP #BladderCancer #UC #Urology @oncodaily @OncoDailyGU
It is our responsibility as urologists to make sure that patients receive the most appropriate treatment and that we consider perioperative treatment with #EVP. Most of the patient patients eligible for #RadicalCystectomy will also be eligible for EVP #BladderCancer #UC #Urology @oncodaily @OncoDailyGU
KEYNOTE-905/EV-303: a major step forward for cisplatin-ineligible MIBC.
Perioperative enfortumab vedotin + pembrolizumab (EVP) significantly improved EFS, OS and pCR versus radical cystectomy alone.
At 2 years:
🎯 EFS 74.7% vs 39.4% — an absolute difference of 35.3 percentage 3 more patients event-free with perioperative EVP!!!
And 57.1% achieved pCR, compared with only 8.6% with surgery (complete TURBT..) alone.
Importantly, benefit was broadly consistent across key subgroups in this older, comorbid population, including patients with ECOG PS 2.
From my perspective as both a urologist and GU oncologist: if a cisplatin-ineligible patient is considered fit enough for radical cystectomy, the patient can (mostly) also receive at least 3 cycles of neoadjuvant EVP!
We finally have the first approved perioperative regimen for cisplatin-ineligible MIBC — and an effective regimen that we should integrate into clinical practice!
@Markuseckstein3 @ViktorGruenwald @JoshMeeks @UniklinikBonn @OncoAlert @urotoday @PTarantinoMD @Uroweb @drenriquegrande @PGrivasMDPhD @amerseburger
@DrYukselUrun @tompowles1 @Uromigos @OncoBellmunt @montypal @DrChoueiri @neerajaiims
@shilpaonc @DrRosenbergMSK @Dr_Aggen
0
0
2
214
Sabine D. Brookman-May retweeted
Rethinking Targeted Therapy in Small Cell Bladder Cancer - Sabine D. Brookman-May
@brookmans76 @Markuseckstein3
oncodaily.com/science/sabine…
@brookmans76 @Markuseckstein3
oncodaily.com/science/sabine…
0
3
5
165